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Abstract
Background: Nasal polyp constitutes a benign growth process in the nasal and sinus mucosa.
RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a protein expressed mainly by
various human cancer cells. It is not only the marker of cancer process and its expression can also
be observed in physiological processes. It is responsible for the regulation of immune cells activity.
DFF45 (DNA fragmenting factor) has been described as a substrate for caspase-3. DFF45 seems to
play an important role in the onset of apoptotic process by acting probably through the regulation
of DNA fragmentation. The aim of the study was to evaluate the ability of nasal polyps to regulate
the cytotoxic immune response and to determine their resistance to apoptosis.
Results: The higher RCAS1 level was identified in lymphocytic nasal polyps, the medium one in
eosinophilic while the lowest was identified in neutrophilic. DFF-45 expression was higher in
eosinophilic than in neutrophilic and lymphocytic nasal polyps.
Conclusion: The changes in DFF-45 level in nasal polyps might indicate a different resistance to
apoptosis mediated by immune cells. The alterations in RCAS1 expression indicate that nasal
polyps have the ability to regulate the cytotoxic immune response.
The breaking of resistance to immune mediated apoptosis in nasal polyps might have a new 
therapeutic impact.
Background
Nasal polyp constitutes a benign growth process in the
nasal and sinus mucosa which is mainly located in the
middle meatus and never in the inferior meatus. The eti-
ology of nasal polyps, which is a common clinical condi-
tion, is not well understood. Infections, allergy and
immunological factors are considered.
Histopathologically polyps surface is covered by a ciliated
pseudostratified epithelium and the subepithelial area is
characterized by an eosinophilic inflammation in more
than 80% of cases. The density of goblet cells in nasal pol-
yps is much lower than in the normal nasal mucosa. The
glands of nasal polyps are long, tubular, of varying shape,
size and type, and their density is more than 10 times
lower than in nasal mucosa [1-3].
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(RCAS1) is a protein which has been demonstrated in var-
ious human cancer cells responsible for tumour escape
from host immunological surveillance. RCAS1 is not only
the marker of cancer process, but its expression has also
been observed in physiological conditions and the devel-
opment of non-neoplastic tumours [4-11]. It has been
demonstrated in the bone marrow, the endometrium, the
decidua, the placenta, Waldeyer's ring and immune medi-
ated diseases. RCAS1 seems to be responsible for the reg-
ulation of cytotoxic cells activity [10-18]. Within
Waldeyer's ring RCAS1 has been expressed by reticular
epithelial cells lining the tonsils. The reticular epithelium
enables the communication between the antigen and the
germinal center, which activates an immunological
response [14]. This role of RCAS1 in the regulation of
immune cells activity has also been confirmed in the cre-
ation of maternal immune tolerance during pregnancy.
The expression of RCAS1 in the healthy endometrium
depended on the hormonal cycle fluctuations and was
related to the immune cytotoxic activity changes [16-18].
DNA fragmentation factor (DFF) is composed of a 40 kDa
protein DFF40, with a nuclease activity, and a 45 kDa pro-
tein inhibitory subunit DFF45 [19]. Since DFF45 is able to
interact with this nuclease as a molecular chaperone and
ensures its correct folding it has been shown to be
required for generating functional DFF40 nuclease [20]. It
has been demonstrated that DFF-45-deficient thymocytes
are more resistant to programmed cell death [21]. In
esophageal and colon carcinoma cells characterized by an
impairment of apoptosis, a decrease of DFF45 level has
also been observed [22]. During apoptosis DFF45 was
described as a substrate for caspase-3. DFF45 seems to
play an important role in the onset of apoptotic process
by acting probably through the regulation of DNA frag-
mentation [23].
The aim of the study was to evaluate the ability to regulate
the cytotoxic immune response (RCAS1 expression) and
to determine the resistance to apoptosis (DFF-45 expres-
sion) in nasal polyps.
Results
Eosinophilic nasal polyps constituted almost 52.5% of
examined samples, the infiltration of lymphocytes was
predominant in 26.3% of nasal polyps and neutrophil
concentration was observed in 21.2%.
RCAS1 expression in nasal polyps
RCAS1 was identified in all examined tissue samples as a
32 kDa band (Figure 1). The highest RCAS1 relative
amount was identified in nasal polyps predominantly
infiltrated by lymphocytes and it was statistically signifi-
cantly higher than in eosinophilic nasal polyps (p = 0.01).
The lowest RCAS1 expression level was observed in neu-
The results of RCAS1 (A), DFF45 (B) and beta-Actin expression in Western blot methodFigu e 1
The results of RCAS1 (A), DFF45 (B) and beta-Actin expression in Western blot method. RCAS represented a 32 kDa band, 
DFF45 a 45 kDa band and beta-Actin a 42 kDa band.Page 2 of 8
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lower than in eosinophilic nasal polyps (p = 0.01) and
statistically significantly lower than in lymphocytic nasal
polyps (p < 0.001). The RCAS1 expression was confirmed
by immunohistochemistry method in all examined tissue
samples. A correlation of RCAS1 expression between
Western blotting and immunohistochemistry was identi-
fied (R = 0.67, p < 0.001). RCAS1 immunoreactivity was
found in superficial layer of pseudostratified ciliated epi-
thelium covering the surface of nasal polyps (Figure 2).
Moreover, RCAS1 expression was also identified in mac-
rophages of polypoid stroma (Figure 3).
DFF45 expression in nasal polyps
DFF45 expression was identified in all examined tissue
samples as a 45 kDa band (Figure 1). DFF45 expression
was statistically significantly higher in eosinophilic nasal
polyps in comparison to lymphocytic nasal polyps (p <
0.0001) and significantly higher in eosinophilic nasal pol-
yps than in neutrophilic (p < 0.001). DFF45 expression
was at a comparable level in neutrophilic and lym-
phocytic nasal polyps.
The obtained results of RCAS1, DFF-45 and Beta-Actin
control protein in examined tissue samples are presented
in Table 1.
The fact that the amount of beta-Actin in all groups of
examined nasal polyps was found to be identical (Table 1)
indicates that the loading of protein was equal in all sam-
ples examined and allows to perform a comparative study
in RCAS1 expression between examined groups.
Discussion
In the presented study statistically significant differences
in RCAS1 and DFF45 expression in nasal polyps were
Nasal polypsFigure 2
Nasal polyps. RCAS1 immunoreactivity in superficial layer of epithelium (vertical arrow).Page 3 of 8
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infiltration type: eosinophils, lymphocytes and neu-
trophils.
The regulation of polypoid growth is biochemically deter-
minated by various factors, like galectin-3, known of anti-
apoptotic activity, which expression is markedly higher in
nasal polyps than in nasal turbinate [27]. Apoptosis is
defined as programmed cell death. It has been reported
that apoptosis mediated through the interaction of Fas
and Fas-L might participate in immune privilege of nasal
polyps [28]. Fas/Fas-L interactions are an important
mechanism in the functional organ development and in
pathological changes such as cancer and immune medi-
Nasal polypsFigure 3
Nasal polyps. RCAS1 positive macrophages (vertical arrow) within polypoid stroma and RCAS1 immunoreactivity in superficial 
layer of epithelium (horizontal arrow).
Table 1: The average relative amounts of RCAS1, DFF-45 and β-Actin in nasal polyps tissue samples with respect to the immune cells 
infiltration.
Nasal polyps divided according to 
immune cell concentration
Average relative amount
of RCAS1 ± SD
Average relative amount
of DFF-45 ± SD
Average relative amount
of beta-Actin ± SD
Eosinophilic nasal polyps (n = 42) 1.3421 (± 0,6464) 0.6261 (± 0.1642) 0.9411 (± 0.2358)*
Lymphocyte infiltration (n = 21) 1.9345 (± 0.7121) 0.3603 (± 0.1157) 0.8722 (± 0.2526)*
Neutrophil infiltration (n = 17) (± 0.2522) (± 0.1409) 0.9308 (± 0.1883)*
• no differences statically significant, (n – number of patients)Page 4 of 8
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of the activity of immune cells [29]. The expression of Fas-
L has been identified in both nasal polyps and nasal tur-
binate mucosa, but has been enhanced in nasal polyps.
Moreover, Fas-L positive cells have been found in the
down growing epithelium of nasal polyps and in the epi-
thelial layer of cystically dilated glands [30]. Fas/Fas-L
interaction results in the activation of the caspase cascade
through FADD (Fas associated death domain) leading to
the DFF-45 dissociation from DFF-40 and liberation of
the DNA-ase responsible for the DNA fragmentation [31].
Ohshima compared FasL and RCAS1 expressions in Reed-
Sternberg cells and trophoblast cells, and revealed that
both proteins activate independently Fas-associated death
domain which activates the caspase cascade and leads to
the apoptosis of target cell. In this way the cells expressing
RCAS1 and Fas-L are responsible for suppression of
immune cytotoxic lymphocytes [13]. In both, Fas-L and
RCAS1 pathways of apoptosis DFF-45/DFF-40 complex
seems to be crucial. In the presented study RCAS1 immu-
nohistochemically was identified only in the pseudostrat-
ified ciliated epithelium covering the surface of nasal
polyps and this localization differs from the reported Fas-
L localization in nasal polyps. RCAS1 positive macro-
phages were identified in polypoid tissue stroma. Until
now RCAS1 positive macrophages have been identified in
the bone marrow where they are responsible for the regu-
lation of maturating erythroblasts [12]. Additionally
RCAS1 positive macrophages have been found in ovarian
endometriosis although they have not been present in the
normal, eutopic endometrium [18]. In sum, it might be
interpreted that RCAS1 positive macrophages might par-
ticipate in the local immune dysfunction in nasal polyps.
The inflammatory infiltrate of nasal polyps consists of
eosinophils, lymphocytes, mast cells, macrophage-like
CD68+ cells [32]. Both eosinophils and lymphocytes are
resistant to Fas-L/Fas mediated apoptosis [33]. The lym-
phocytes that infiltrate nasal polyps have been defined to
be predominantly memory T cells in an activated status
and produced a mixed Th1/Th2 cytokine pattern (IFN-
gamma and IL-5) [34]. Cytokines, including IL-5, IFN-
gamma, GM-CSF also participate in delaying of the death
process in these cells, thus contributing to developing of
tissue and blood eosinophilia [32,34,35]. The lym-
phocytes infiltrated nasal polyps in our study were charac-
terized by the highest RCAS1 expression level and a
statistically significantly lower DFF-45 expression than
eosinophilic nasal polyps. Low DFF-45 level might indi-
cate that the polyps infiltrated by lymphocytes are more
resistant to immune mediated apoptosis than eosi-
nophilic nasal polyps. Additionally, the expression of
RCAS1, a factor participating in the suppression of cyto-
toxic activity, might help polypoid tissue to avoid
immune cytotoxicity.
The etiology of neutrophilic nasal polyps is connected
with bacterial inflammation. It has been postulated that
superantigens derived mainly from Staphylococcus aureus
might be potent activators of T cells and might therefore
participate in the formation of nasal polyps [28]. Superan-
tigens are able to activate the immune cytotoxic response
without antigen presenting cells which results in the expo-
sure of polypoid tissue to immune mediated apoptosis. In
our study neutrophilic nasal polyps were characterized by
a comparable level of DFF-45 as lymphocytic nasal polyps
and lower than eosinophilic nasal polyps. We suspect that
neutrophilic nasal polyps, similarly to lymphocytic nasal
polyps, are more resistant to immune mediated apoptosis
than eosinophilic nasal polyps, which might compensate
the immune cytotoxicity. The observed decreased RCAS1
expression in neutrophilic nasal polyps might result from
the immune cells infiltration pattern.
Conclusion
The changes in DFF-45 level in nasal polyps regarding the
type of immune cell infiltration might indicate a different
resistance to apoptosis mediated by immune cells. The
alterations in RCAS1 expression indicate that nasal polyps
have the ability to regulate the cytotoxic immune
response.
Methods
Clinical material
Tissue samples were derived from ENT Head and Neck Sur-
gery Department of the Jagiellonian University during rou-
tine endonasal sinus surgery. In all cases patient's consent
was obtained. The approval for the research program from
the Ethical Committee of the Jagiellonian University in
Krakow: KBET/379/13/2003 was also granted. We
recruited 300 patients from the patients that undergone
functional endoscopic sinus surgery between January 2003
and January 2005. From this group of patients 80 patients
were randomly selected to our study. We obtained 80 tis-
sue samples. All tissue samples were histopathologically
verified. Pathological analysis using the classical hematox-
ylin and eosin staining techniques after fixation in forma-
lin of the surgically removed material was performed in
the Pathology Department of the Jagiellonian University
by an experienced pathologist. The predominant immune
cell infiltration in nasal polyps was determined. According
to the predominant immune cell infiltration the tissue
samples were divided into three main groups: nasal polyps
predominantly infiltrated by eosinophils (eosinophilic
nasal polyps)- 42 cases, nasal polyps predominantly infil-
trated by lymphocytes (lymphocytic nasal polyps)- 21
cases and nasal polyps predominantly infiltrated by neu-
trophils (neutrophilic nasal polyps)-17 cases.
The clinical characteristics of subjects is presented in Table
2.Page 5 of 8
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The Western blot analysis was necessary to elucidate the
doubts concerning the specifity of anti-RCAS1 mono-
clonal antibodies. Engelsberg informs that anti-RCAS1
monoclonal antibodies recognize not only RCAS1 but
also Thomsen-Friedenreich antigen (TF antigen) and Tn
antigen in immunohistochemistry method [24]. In gen-
eral TF (Galβ1-3GalNAc) and Tn (O-linked glycan struc-
tures like terminal GalNAc) antigens are thought to be
linked to cells adhesion, invasion and metastases of can-
cer cells. The analysis performed by Engelsberg of recom-
binant RCAS1-GST fusion protein confirmed RCAS1
molecular weight described earlier by Tsuchija as a 32 kDa
band in the Western blot method [24,25]. Tsuchija per-
formed the analysis of molecular cloning EBAG9/RCAS1
gene. TF antigen is recognized by the jackfruit lectin, jaca-
lin and molecular masses were established at: 230, 188,
168, 120 and 58 kDa levels [26]. Then we were sure that
we recognized RCAS1 identifying its molecular weight at
32 kDa in the Western blot method.
Preparation of tissue extracts
Tissue samples (app. 0.5 × 0.5 × 0.5 cm) were obtained
from the nasal polyps present within the middle nasal
meatus collected during routine endonasal sinus surgery
and were immediately frozen. The specimens were mixed
with complete proteinase inhibitor cocktail (Roche, Ger-
many) and homogenized on ice-bath in glass-glass Potter-
Elvejhem homogenizer. The resulting suspensions were
mixed with an equal volume of SDS sample lysis buffer
(4% SDS, 20% glycerol, 125 mM Tris-HCl pH 6.8) and
boiled in water bath for 5 minutes. The chilled samples
were then centrifuged at 16,000 g at room temperature for
15 minutes. The collected supernatants were used for fur-
ther analysis.
Western blotting
The total protein content in the obtained supernatants
was measured using BCA assay kit and different sample
volumes (usually in the range of 2–10 µl) equivalent of 50
µg of the total protein were then loaded on SDS-PAGE
tris-tricine peptide-separating gels. Prestained broad range
molecular weight proteins standard (Bio Rad, USA) was
used in gel marker lane. Following electrophoresis the gels
were electrotransferred onto Immobilon-P polyvinyli-
dene difluoride (PVDF) 0.45 µm membrane (Millipore,
USA) in the buffer containing 10 mM 3- [cyclohexyloam-
ino]-1-propanesulfonic acid (CAPS) pH 11, supple-
mented with 10% methanol. The obtained membrane
blots were blocked overnight by gentle agitation in 5%
bovine albumin in TST buffer (0.01 M Tris-HCl, pH 7.4,
0.9%NaCl), 0.5% Tween-20). All described procedures
were performed at room temperature. Albumin solution
was discarded and the membranes were then agitated for
2 hrs in TST with the mouse monoclonal anti-RCAS1 IgM-
class antibody, 1: 4 000 dilution (Medical and Biological
Laboratories, Japan), polyclonal rabbit IgG antibody
against DFF45 (Abcam, UK), monoclonal mouse IgG anti-
body against beta-Actin (Sigma, USA). The membranes
were then subjected to 4 cycles of washings in TST, 5 min-
utes each, and immersed for agitation in the 1 : 2 000 dilu-
tion of SIGMA biotinylated anti-mouse IgM µ-chain
specific antibodies for 2 hours. After 4 cycles of washings
the membranes were then treated in 1 : 2 000 dilution of
ExtrAvidin alkaline phosphatase conjugate (SIGMA, USA)
for 2 hours and finally washed twice in TST and twice in
TST without Tween-20. Color reaction was developed
with the use of Fast Red TR/Naphtol AS-MX tablet set
(SIGMA, USA). A sufficient bands intensity was obtained
usually following 5-minute period of developing.
Obtained immunoblotts were then rinsed with distilled
water and air-dried.
Computer-aided image analysis
Fluor-S MultiImager (BioRad, USA) was used to scan
immunoblotted membranes and a QuantityOne software
(BioRad, USA) was used to quantitate band intensities. All
calculations were performed on RCAS1 antigen band hav-
ing molecular mass of 32 kDa, DFF45 protein having
molecular mass of 45 kDa and beta-Actin as a 42 kDa
band. The intensities of these bands were expressed in
arbitrary relative units and one unit (U) was defined as a
band intensity produced in the reference sample. This ref-
erence sample was randomly chosen but it was exactly the
Table 2: The characteristics of subjects.
Variable Mean age BMI (body mass index) Sex: Male Female Surgical procedure
Eosinophilic infiltration (n = 42) 42.67 (± 14.09) 25.57 (± 3.38) 17 (40%) 25 (60%) polypectomy 100%
ethmoidectomy 93%
sphenoidectomy 10%
maxillectomy 30.7%
Lymphocytes infiltration (n = 21) 42.62 (± 17.09) 26.25 (± 3.24) 7 (33.3%) 14 (66.6%) polypectomy 100%
ethmoidectomy 94%
sphenoidectomy 13%
maxillectomy 30%
Neutrophils infiltration (n = 17) 43.6 (± 13.50) 26.14 (± 1.9) 6 (33%) 12 (67%) polypectomy 100%
maxillectomy 33%Page 6 of 8
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The typical procedure of RCAS1 quantization was as fol-
lows: the scanned immunoblot membrane contained one
lane of molecular mass standards, while one lane of the
sample used as a reference to calibrate RCAS1 amount and
12 lanes containing unknown samples. The location of 32
kDa RCAS1 bands in reference and unknown lanes was
identified according to the lane containing molecular
mass standard. The 32 kDa RCAS1 band intensities in ref-
erence and in unknown lanes were then calculated and
expressed in pixel number units. These units were divided
by pixel number of reference lane band which resulted in
relative intensity units "U". The resulting intensity of ref-
erence lane band was always 1.00 U while the intensities
of bands from 12 unknown sample lanes on the same
membrane changed according to RCAS1 level (e.g., if
RCAS1 amount in a given sample was 2 times higher than
this in reference sample the result was 2.00 U. If the
RCAS1 amount was twice lower, then the result was 0.50
U). As mentioned earlier, because all immunoblots con-
tained the same RCAS1 quantity standard and all lanes
were loaded with the same amount of total protein (50
µg), the determined values were highly repetitive and
independent of experiment conditions. The RCAS1 total
amount in examined tissue samples was recognized rela-
tively, which was necessary because no RCAS1 standard is
available. The result always shows relative amount of
RCAS1 32 kD antigen in 50 µg of total sample protein. All
the bands were analyzed for the recognition of DFF45 and
beta-Actin proteins in the same way.
Immunohistochemistry
The immunohistochemistry method was performed to
localize the RCAS1 expression in nasal polyps. The immu-
nohistochemical analysis was performed in the Depart-
ment of Pathology of the Jagiellonian University. 5 µm
thick slides were deparaffinized, rehydrated and rinsed in
distilled water. Endogenous peroxidase activity was
blocked by 8 min incubation in 3% H2O2 at room tem-
perature. The slides were then rinsed and immersed in
boiling citrate buffer (pH 6,0) in a microwave oven with
three changes of buffer for 5 minutes each. For the immu-
nolocalisation of RCAS1 the slides were treated with the
mouse monoclonal antibody Anti-RCAS1 (Medical and
Biological Laboratories, Naka-ku Nagoya, Japan in DAKO
Antibody Diluent with Background Reducing Compo-
nents-DAKO, Denmark, dilution 1:1000) in moist cham-
ber overnight. The slides were subsequently rinsed in TBS
buffer (pH 7,6) and incubated with the secondary anti-
body (DAKO Envision TM+ System Labelled Polymer
HRP – anti mouse (DAKO, Denmark) at room tempera-
ture for 30 minutes. Visualisation was performed using
AEC (3-amino-9-ethyl-carbazole) as a chromogen (AEC
Substrate Chromogen ready-to-use, DAKO, Denmark) at
room temperature for 10 minutes. Sections were counter-
stained with hematoxylin and mounted in glycergel. We
assumed that positive reactivity for RCAS1 occurred when
we observed a granular cytoplasmic (rarely membranous)
staining pattern in at least 10% of cells with the following
intensity: 0- no reactivity; 1-weak (10–25% positive cells);
2-moderate (26–50% positive cells); 3-strong (51–100%
positive cells).
Statistical analysis
The distribution of variables in the examined groups of
patients checked with the use of the Shapiro-Wilk test
showed that all of them were different from normal.
Therefore, non-parametric testing was employed. Statisti-
cal significance between the groups was determined by
the Kruskal-Wallis analysis of variance (ANOVA) test. The
Mann-Whitney U test was then used when appropriate.
Data in Table 2 were presented as means ± standard error
of the mean (SEM). A p value of <0.05 was accepted as sta-
tistically significant. The Spearman rank test was used to
evaluate interclass correlation coefficients. All calculations
were carried out with the use of STATISTICA software v. 6
(StatSoft, USA, 2001).
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